- Researchers say people who took tirzepatide saw a significant reduction in their blood pressure over 36 weeks.
- Tirzepatide, which is prescribed for type 2 diabetes (Mounjaro) and obesity (Zepbound), is being studied for its effects on cardiovascular conditions as well.
- The new findings further support the potential role of the drug in treating a host of conditions, including high blood pressure, obesity, and diabetes.
Researchers are reporting that people who took tirzepatide, a type 2 diabetes and obesity medication, showed a significant reduction in blood pressure levels after 36 weeks.
They reported their findings in a
Tirzepatide, which was originally indicated for the treatment of diabetes and sold under the trade name Mounjaro, was approved for the treatment of obesity under the name Zepbound in November 2023.
Due to well-established links between obesity and cardiovascular conditions, researchers are taking a closer look at how tirzepatide and similar drugs, such as semaglutide (Ozempic and Wegovy), known as GLP-1 RAs can impact heart health.
Tirzepatide is a combination of GLP-1 RA and
In their research letter, the scientists said that blood pressure improved in people who took tirzepatide over 36 weeks, compared to study participants who took a placebo.
However, the researchers said they did not establish a dose-dependent improvement, meaning that individuals who took more of the drug did not see better results than those who took less of it.
Additionally, it is also unclear from the research whether blood pressure decreased solely due to weight loss or if there was an additional mechanism at work due to the medication.
Experts do say that the findings hint at further benefits of the drug beyond diabetes and obesity.
“These are statistically significant and clinically…
Read the full article here